

-10-

- 129
121. (New) The method of claim ¹²⁸~~120~~, wherein the biomolecule is a fusion protein.
- 130
122. (New) The method of claim ¹²⁹~~121~~ wherein the cell is a mammalian cell.
- 131
123. (New) The method of claim ¹²⁹~~121~~ wherein the cell is a pathogen cell.

REMARKS

Claims 1, 2, 6-12, 23-27, 50-54 and 56-58 have been canceled. Claims 59-123 have been added. Below are some of the locations in the specification where support for new Claims 59-123 can be found.

<u>Claim</u>	<u>Support</u>
59	original claim 7; for "protein target components" see page 13, lines 3-9, page 19, lines 2-7, page 20, lines 4-5, page 22, lines 22-27, page 36, lines 8-10 and page 38, lines 4-7
60	original claim 8
61	original claim 8
62	page 10, lines 6-7
63	page 10, lines 6-7
64	regarding target enzymes, see page 15, lines 8-10, page 15, lines 20-23, and page 28, lines 10-13. The Examples illustrate <i>E. coli</i> prolyl tRNA synthetase and <i>S. aureus</i> methionyl tRNA synthetase as target cell components.
65	page 11, line 6
66	The Examples illustrate fusion proteins as biomolecules binding to target enzymes.
67	original claim 10
68	original claim 9
69	page 10, lines 6-11
70	regarding target enzymes, see page 15, lines 8-10, page 15, lines 20-23, and page 28, lines 10-13. The Examples illustrate <i>E. coli</i> prolyl tRNA synthetase and <i>S.</i>

-11-

aureus methionyl tRNA synthetase as target cell components.

- 71 page 11, line 6
- 72 page 11, line 6
- 73 The Examples illustrate fusion proteins as biomolecules binding to target
enzymes.
- 74 original claim 10
- 75 original claim 9
- 76 original claims 1 and 3
- 77 original claim 6
- 78 original claims 1, 4 and 6
- 79 original claims 1 and 4; page 10, lines 6-7
- 80 original claims 1 and 4; page 10, lines 6-7
- 81 regarding target enzymes, see page 15, lines 8-10, page 15, lines 20-23, and page
28, lines 10-13. The Examples illustrate *E. coli* prolyl tRNA synthetase and *S.*
aureus methionyl tRNA synthetase as target cell components.
- 82 page 11, line 6
- 83 original claims 1 and 4; The Examples illustrate fusion proteins as biomolecules
binding to target enzymes.
- 84 original claims 1 and 4; page 10, lines 6-11
- 85 regarding target enzymes, see page 15, lines 8-10, page 15, lines 20-23, and page
28, lines 10-13. The Examples illustrate *E. coli* prolyl tRNA synthetase and *S.*
aureus methionyl tRNA synthetase as target cell components.
- 86 page 11, line 6
- 87 page 11, line 6
- 88 The Examples illustrate fusion proteins as biomolecules binding to target
enzymes.
- 89 original claim 7; page 11, line 6
- 90 original claim 8
- 91 original claims 7 and 8; page 11, line 6
- 92 page 5, lines 9-19

-12-

93 original claim 7; page 11, line 6; The Examples illustrate fusion proteins as
biomolecules binding to target enzymes.
94 page 10, lines 6-7
95 page 10, lines 6-7
96 regarding target enzymes, see page 15, lines 8-10, page 15, lines 20-23, and page
28, lines 10-13. The Examples illustrate *E. coli* prolyl tRNA synthetase and *S.*
aureus methionyl tRNA synthetase as target cell components.
97 original claim 10
98 original claim 9
99 page 5, lines 9-19
100 original claim 8; page 5, lines 9-19; page 10, lines 6-11
101 original claim 10
102 original claim 9
103 original claims 1, 3 and 4; page 11, line 6
104 original claims 8 and 9
105 original claims 1, 3, 4 and 8; page 11, line 6
106 page 5, lines 9-19
107 original claims 1, 3, and 4; page 11, line 6; The Examples illustrate fusion
proteins as biomolecules binding to target enzymes.
108 page 10, lines 6-7
109 page 10, lines 6-7
110 regarding target enzymes, see page 15, lines 8-10, page 15, lines 20-23, and page
28, lines 10-13. The Examples illustrate *E. coli* prolyl tRNA synthetase and *S.*
aureus methionyl tRNA synthetase as target cell components.
111 original claim 23
112 original claim 23
113 original claim 23
114 original claim 23; page 11, line 6
115 original claim 23; The Examples illustrate fusion proteins as biomolecules
binding to target enzymes.

-13-

- 116 original claims 10 and 23
- 117 original claims 9 and 23
- 118 original claims 23 and 25
- 119 original claims 23 and 25
- 120 original claims 23 and 25; page 11, line 6
- 121 original claims 23 and 25; page 11, line 6; The Examples illustrate fusion proteins
as biomolecules binding to target enzymes.
- 122 original claims 10, 23 and 25; page 11, line 6; The Examples illustrate fusion
proteins as biomolecules binding to target enzymes.
- 123 original claims 9, 23 and 25; page 11, line 6; The Examples illustrate fusion
proteins as biomolecules binding to target enzymes.

Cancellation of pending claims and redrafting of the claims as newly added claims 59-123 has been done to simplify and make more clear the language of the claims. The newly added claims address the concerns in regard to the Bostian *et al.* (WO 96/40979) reference raised by the Examiner in the Office Action of May 23, 2002, and in a telephonic conference with the undersigned attorney on October 18, 2002. In the newly added claims, the biomolecule interacts with the target component by binding to it. The language of the claims does not encompass RNA-RNA or RNA-DNA interactions as biomolecule and target component interactions.

-14-

CONCLUSION

The Examiner is respectfully requested to consider the above amendments and remarks. If the Examiner feels that a telephone conference would expedite prosecution of this case, the Examiner is invited to call the undersigned attorney.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Carol A. Egner
Carol A. Egner
Registration No. 38,866
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: December 12, 2002